Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...

At Shionogi, a Japanese pharmaceutical company, executives pointed out that COVID is still flaring in Japan. In Japan, ...

Pfizer's pipeline features quite a few promising candidates that could be big winners in the future. CEO Albert Bourla highlighted some of them in the Q3 earnings call. Probably none is as eagerly ...

In life, there’s a common expression that also carries over into the dividend investing world: If it seems too good to be true, it usually is ...

It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, ...

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...

Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now ...